<DOC>
	<DOCNO>NCT01216293</DOCNO>
	<brief_summary>The purpose study evaluate effect dexlansoprazole modify release ( MR ) , daily ( QD ) , bone homeostasis .</brief_summary>
	<brief_title>Effect Dexlansoprazole Bone Homeostasis</brief_title>
	<detailed_description>Research drug affect bone homeostasis show change level bone formation resorption biomarkers . This study evaluate effect dexlansoprazole bone homeostasis assess change biochemical marker bone formation bone resorption . This study also assess change bone mineral density dual-energy x-ray absorptiometry scan marker bone homeostasis . The study consist 12-week screening period , 26-week treatment period total 5 visit treatment period follow-up visit Week 52 bone mineral density assessment .</detailed_description>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Is postmenopausal female general good health body mass index ≥18 ≤30 kg/m2 . Must biochemical marker bone formation , procollagen type 1 Nterminal propeptide bonespecific alkaline phosphatase , bone resorption , crosslinked βCterminal telopeptide type 1 collagen urine Ntelopeptide within normal postmenopausal female range . Has take proton pump inhibitor medication within 6 month prior screen agrees refrain take last dose study drug , except studysupplied dexlansoprazole esomeprazole . Has parathyroid hormone thyroid stimulate hormone level outside reference range Week 12 25OHD level &lt; 32 ng/mL Week 2 . Has baseline bone mineral density dualenergy xray absorptiometry define Tscore low 2.0 total hip , spine , femoral neck base Caucasian reference value . Has disorder strongly associate osteoporosis Has history lumbar laminectomy , vertebroplasty , vertebral deformity severe lumbar scoliosis interfere measurement performance dual xray absorptiometry . Has history clinical manifestation uncontrolled significant metabolic , hematologic , pulmonary , cardiovascular , gastrointestinal , neurologic , hepatic , renal , urologic , immunologic , psychiatric disorder determine investigator may affect ability subject participate potentially confound trial result . Has family history genetic bone disorder .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>